TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3772891
Drug: Single perioperative
Normalized name: ENSURE SURGERY PERIOPERATIVE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single perioperative dose of mezlocillin
Study: 3772891
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of mezlocillin
Study: 3772891
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of cefoxitin
Study: 26832658
Drug: IAI 2
Normalized name: Intravitreal aflibercept injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: IAI 2 mg every 4 weeks (2q4) in patients without prior anti-VEGF treatment
Study: 26832658
Drug: IAI 2
Normalized name: Intravitreal aflibercept injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: IAI 2 mg every 8 weeks after 5 monthly doses (2q8) in patients without prior anti-VEGF treatment
Study: 26832658
Drug: Macular laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Macular laser photocoagulation in patients without prior anti-VEGF treatment
Study: 23897775
Drug: Adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 40 mg every other week for 10 weeks
Study: 22293719
Drug: 0.1% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% ropivacaine (basal 12 ml/h; bolus 4 ml)
Study: 22293719
Drug: 0.4% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4% ropivacaine (basal 3 ml/h; bolus 1 ml)
Study: 20598077
Drug: Dalteparin low-molecular-weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin low-molecular-weight heparin (LMWH) 5000 anti-Xa units, subcutaneously once daily for 6 months.
Study: 20598077
Drug: Placebo, subcutaneously
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, subcutaneously once daily for 6 months.
Study: 20598077
Drug: Dalteparin low-molecular-weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin low-molecular-weight heparin (LMWH) 5000 anti-Xa units.
Study: 17637403
Drug: Postdischarge enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postdischarge enoxaparin (40 mg once daily for 20 days)
Study: 17637403
Drug: Placebo (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (once daily for 20 days)
Study: 17637403
Drug: Postdischarge enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postdischarge enoxaparin (40 mg once daily)
Study: 15310644
Drug: NOBLOCK group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: NOBLOCK group (no neuromuscular blocking agent)
Study: 9661545
Drug: Preemptive epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive epidural bupivacaine (0.66 mL/kg 0.25%) with morphine (0.02 mg/kg) administered caudally before surgery
Study: 9661545
Drug: Postincisional administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postincisional administration of the same bupivacaine-morphine mixture after surgery
Study: 9661545
Drug: Preemptive epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive epidural bupivacaine with morphine
Study: 9661545
Drug: Postincisional administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postincisional administration of the same bupivacaine-morphine mixture
Study: 7714226
Drug: Nefazodone 100
Normalized name: NEFAZODONE 100MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefazodone 100 mg twice daily
Study: 7714226
Drug: Nefazodone 200
Normalized name: NEFAZODONE 200MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefazodone 200 mg twice daily
Study: 7714226
Drug: Imipramine 50
Normalized name: trimipramine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine 50 mg twice daily
Study: 2757895
Drug: Alpha-interferon (Roferon-A)
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alpha-interferon (Roferon-A) administered as an intra-muscular injection (3 x 10(6) iu) once-a-day over 3 days
Study: 54852
Drug: Gelatin infusion
Normalized name: Gelatin
DrugBank: Gelatin (DB11242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelatin infusion
Study: 54852
Drug: Dextran 60
Normalized name: dextran 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextran 60 infusion
Study: 27894985
Drug: Co-infected cases
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-infected cases receiving antiretroviral therapy (ART)
Study: 11686419
Drug: Low-dose inhaled
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose inhaled fluticasone propionate (FP) 44 microg, two puffs twice daily for 4 weeks
Study: 11686419
Drug: Oral zafirlukast
Normalized name: Zafirlukast
DrugBank: Zafirlukast (DB00549)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral zafirlukast (ZK) 20 mg, twice daily for 4 weeks
Study: 11301564
Drug: Oral ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ganciclovir 1,000 mg every 3 hours (six times a day)
Study: 11301564
Drug: Oral ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ganciclovir 1,000 mg four times a day
Study: 11301564
Drug: Oral ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ganciclovir 1,000 mg three times a day
Study: 11301564
Drug: Single 5-mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 5-mg/kg intravenous infusion of ganciclovir
Study: 11301564
Drug: Oral ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ganciclovir 6,000 mg/day
Study: 11301564
Drug: Oral ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ganciclovir 3,000 mg/day and 4,000 mg/day
Study: 11301564
Drug: Oral ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ganciclovir 4,000 mg/day and 6,000 mg/day
Study: 3062257
Drug: OPA therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPA therapy (2 cycles) for stage I/IIA
Study: 3062257
Drug: OPA therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPA therapy (2 cycles) and COMP therapy (2 cycles) for stage IIB/IIIA
Study: 3062257
Drug: OPA therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPA therapy (2 cycles) and COMP therapy (4 cycles) for stage IIIB/IV
Study: 3062257
Drug: Radiotherapy (dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy (dosage of 35, 30 or 25 Gy depending on chemotherapy extent)
Study: 26147010
Drug: P2G12 (monoclonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: P2G12 (monoclonal antibody derived from transgenic tobacco)
Study: 23453465
Drug: Lateral position
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lateral position (Group L)
Study: 20034685
Drug: Metformin 850
Normalized name: metFORMIN 850 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 850 mg/d + Atorvastatin 10 mg
Study: 16918659
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg x kg(‐1) of ketamine before surgery (Group II)
Study: 16918659
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg x kg(‐1) of ketamine after surgery (Group III)
Study: 15479482
Drug: Bevacizumab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (5 mg/kg I.V. every 2 weeks)
Study: 9302444
Drug: Testosterone cypionate
Normalized name: Testosterone Cypionate
DrugBank: Testosterone cypionate (DB13943)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone cypionate 200 mg intramuscularly every 2 weeks for 3 months
Study: 8391304
Drug: Granisetron (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron (40 micrograms kg−1) as a single prophylactic 5-min infusion
Study: 8391304
Drug: High-dose metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose metoclopramide (loading dose of 3 mg kg−1 followed by maintenance dose of 4 mg kg−1 infused over 8 h) plus dexamethasone (12 mg as a 30-min infusion)
Study: 8391304
Drug: High-dose metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose metoclopramide plus dexamethasone
Study: 27312945
Drug: Testosterone therapy
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone therapy (intramuscular testosterone undecanoate)
Study: 15953008
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of asparaginase (ASP) and steroids during the postinduction intensification phase, with high-risk patients receiving thrice the steroid dose compared to standard-risk patients.
Study: 15953008
Drug: Older patients
Normalized name: black alder pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Older patients (≥10 years) receiving the same treatment.
Study: 15953008
Drug: High-risk (HR)
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-risk (HR) treatment group receiving the same treatment.
Study: 12748666
Drug: Interferon-alpha (IFN)
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha (IFN) treatment for a median duration of 5 months (1-18 months) until a median of 1 month prior to transplantation.
Study: 12748666
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no IFN treatment).
Study: 12748666
Drug: Interferon-alpha (IFN)
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha (IFN) treatment.
Study: 9579718
Drug: roxithromycin 150
Normalized name: roxithromycin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxithromycin 150 mg bd
Study: 9579718
Drug: co-amoxiclav 625
Normalized name: CO
DrugBank: Carbon monoxide (DB11588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: co-amoxiclav 625 mg tds
Study: 7644852
Drug: Buflomedil (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buflomedil (400 mg in bolus)
Study: 7644852
Drug: Naftidrofuryl (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naftidrofuryl (200 mg in bolus)
Study: 2528004
Drug: TE‐031 (clarithromycin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TE‐031 (clarithromycin) at a daily dosage of 400 mg in 2 divided doses
Study: 2528004
Drug: JM (josamycin)
Normalized name: JM
DrugBank: Josamycin (DB01321)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JM (josamycin) at a daily dosage of 1,200 mg in 3 divided doses
Study: 766340
Drug: Daily rifampicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily rifampicin plus ethambutol (ER7)
Study: 766340
Drug: Twice-weekly rifampicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly rifampicin plus ethambutol (ER2)
Study: 766340
Drug: Once-weekly rifampicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly rifampicin plus ethambutol (ER1)
Study: 766340
Drug: Daily for
Normalized name: Men's Daily Formula Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily for 2 months and then once-weekly rifampicin plus ethambutol (ER7ER1)
Study: 766340
Drug: Standard retreatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard retreatment regimen of daily ethionamide plus pyrazinamide plus cycloserine (EtZC)
Study: 25605528
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with standardized JCP extract for five months over the pollen season
Study: 21816071
Drug: 3.0 g
Normalized name: LACTIC ACID 23.0 g in 1 L TOPICAL SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 g n‐3 LC‐PUFA/d
Study: 21816071
Drug: 3.2 g
Normalized name: OATMEAL 2.3 g in 113.2 g TOPICAL CREAM [EczeNil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.2 g γ‐linolenic acid/d
Study: 21816071
Drug: 1.6 g
Normalized name: GLYCERIN 1241.6 g in 1 L TOPICAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.6 g n‐3 LC‐PUFA + 1.8 g γ‐linolenic acid/d
Study: 21816071
Drug: 3.0 g
Normalized name: LACTIC ACID 23.0 g in 1 L TOPICAL SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 g olive oil
Study: 18473961
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose cytarabine with or without etoposide or mitoxantrone
Study: 18473961
Drug: Timed sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timed sequential chemotherapy regimens
Study: 15267080
Drug: Nicotine (21-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (21-mg transdermal patch)
Study: 9085324
Drug: Train-of-four (TOF)
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Train-of-four (TOF) dosing of vecuronium
Study: 9085324
Drug: Standard clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard clinical assessment dosing of vecuronium
Study: 27163498
Drug: Delayed-release gastroresistant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-release gastroresistant formulation of ketoprofen under fed conditions
Study: 27163498
Drug: Delayed-release gastroresistant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-release gastroresistant formulation of ketoprofen under fasting conditions
Study: 22781424
Drug: Cardiac resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronization therapy (CRT) for patients with LBBB
Study: 22781424
Drug: Cardiac resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronization therapy (CRT) for patients without LBBB
Study: 20159726
Drug: NPPV therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPPV therapy
Study: 18316137
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg/day
Study: 12814146
Drug: Telithromycin 800
Normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telithromycin 800 mg once daily for 7-10 days
Study: 12814146
Drug: Comparator antibacterials
Normalized name: Dermoplast Antibacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator antibacterials (amoxicillin 1000 mg three-times daily, clarithromycin 500 mg twice daily, trovafloxacin 200 mg once daily)
Study: 8607489
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with omeprazole 20 mg b.i.d. plus amoxicillin 1 g b.i.d. and azithromycin 500 mg mane (for the first 3 days)
Study: 8607489
Drug: Double therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double therapy with omeprazole 20 mg b.i.d. plus amoxicillin 1 g t.i.d.
Study: 1898142
Drug: Magnesium therapy
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium therapy (178 mEq over the first 4 postoperative days)
Study: 6359047
Drug: Vidarabine 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vidarabine 15 mg/kg/d
Study: 6359047
Drug: Vidarabine 30
Normalized name: vidarabine 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vidarabine 30 mg/kg/d
Study: 31589553
Drug: Insulin Resistance
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin Resistance (IR) prevalence measurement
Study: 29401328
Drug: Statin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin treatment under ACC/AHA guidelines
Study: 16281429
Drug: Intravenous immune
Normalized name: Intravenous immune globulin (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immune globulin (IVIg)
Study: 12002292
Drug: Gonadotropin‐releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotropin‐releasing hormone analogue (GnRHa) for 1 month
Study: 12002292
Drug: Gonadotropin‐releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotropin‐releasing hormone analogue (GnRHa) for 3 months
Study: 12002292
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA) 15 mg for 3 months
Study: 9653613
Drug: Reduced-dose lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Reduced-dose lispro before dinner (20% reduction) and increased NPH at bedtime (125% of usual dose)
Study: 9653613
Drug: Usual-dose lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Usual-dose lispro plus usual-dose NPH before dinner
Study: 9653613
Drug: Standard premeal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard premeal human regular insulin and pre-bedtime NPH insulin (control)
Study: 8593015
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg oral valaciclovir
Study: 8593015
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg [14C]valaciclovir
Study: 2569686
Drug: OKY-046 80
Normalized name: OKI-179
DrugBank: OKI-179 (DB17583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OKY-046 80 mg (L group)
Study: 2569686
Drug: OKY-046 400
Normalized name: OKI-179
DrugBank: OKI-179 (DB17583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OKY-046 400 mg (H group)
Study: 31171523
Drug: Ticagrelor plus
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor plus aspirin (large artery atherosclerosis)
Study: 31171523
Drug: Clopidogrel plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel plus aspirin (large artery atherosclerosis)
Study: 28427362
Drug: Budesonide/formoterol maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol maintenance and reliever therapy (MRT)
Study: 28427362
Drug: Higher, fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher, fixed-dose budesonide plus as-needed terbutaline
Study: 7778957
Drug: Intravenous ceftizoxime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ceftizoxime sodium (1 g every 12 hours) or ceftriaxone sodium (1 g every 24 hours) followed by oral cefixime (400 mg every 24 hours) after meeting criteria for switch.
Study: 2181111
Drug: ELISA for
Normalized name: pseudopterogorgia elisabethae extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: ELISA for antibodies to B. gingivalis and T. denticola
Study: 31934993
Drug: BCD-132 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCD-132 (100 to 1000 mg intravenous infusion)
Study: 23704673
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus lifestyle (M+L)
Study: 23704673
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (M+R, M, M+L)
Study: 21585061
Drug: Pricking bleeding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pricking bleeding therapy (applied to specific points on the thumb and auricular helix), once daily for 7 days.
Study: 21585061
Drug: Ultrasonic atomizing
Normalized name: Atomic Balm
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasonic atomizing inhalation (UAI), once daily for 7 days for 15 minutes.
Study: 21585061
Drug: Pricking bleeding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pricking bleeding therapy
Study: 21585061
Drug: Ultrasonic atomizing
Normalized name: Atomic Balm
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasonic atomizing inhalation (UAI)
Study: 19532041
Drug: Antiepileptic drugs
Normalized name: ANTIEPILEPTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiepileptic drugs (add-on treatment)
Study: 19532041
Drug: Monotherapy antiepileptic
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy antiepileptic drugs (head-to-head trials)
Study: 16904458
Drug: Topical alprostadil
Normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical alprostadil cream 100 microg
Study: 16904458
Drug: Topical alprostadil
Normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical alprostadil cream 200 microg
Study: 16904458
Drug: Topical alprostadil
Normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical alprostadil cream 300 microg
Study: 16904458
Drug: Topical alprostadil
Normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical alprostadil cream (all doses)
Study: 10619583
Drug: irbesartan (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: irbesartan (150 mg)
Study: 2042654
Drug: Calcium citrate,
Normalized name: calcium citrate, calcium malate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium citrate, 950 mg four times a day
Study: 2042654
Drug: Aluminum hydroxide
Normalized name: Aluminum Hydroxide
DrugBank: Aluminum hydroxide (DB06723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminum hydroxide (2.4 g/d)
Study: 31451360
Drug: Self-administered web-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered web-based decision aid
Study: 16130190
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg mycophenolate mofetil (MMF) twice daily
Study: 6218098
Drug: Mezlocillin treatment
Normalized name: mezlocillin
DrugBank: Mezlocillin (DB00948)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mezlocillin treatment
Study: 19232039
Drug: Nebulized formoterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized formoterol fumarate inhalation solution (Perforomist, FFIS 20g BID)
Study: 19232039
Drug: Ipratropium and
Normalized name: Ipratropium and salbutamol only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipratropium and albuterol combined in a metered-dose inhaler (MDI) (Combiventy, IPR-ALB, QID)
Study: 17925883
Drug: Methylphenidate transdermal
Normalized name: methylphenidate Transdermal System
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate transdermal system (MTS) applied on the hip for nine hours.